In the original publication [1], there was a mistake in Figure 4. In Figure 4C, S. aureus-BBR vs. MRSA-Control, S. aureus-TA vs. MRSA-BBR, and MRSA-TA vs. MRSA-BBR/TA MIX were repeated. All the pictures were combined using PPT software and then exported. Because the experimental steps for detecting the effects of the drugs on S. aureus and MRSA were exactly the same, and the experimental results of the above groups were similar, this led to an insertion error. However, the description of the results and the conclusion are correct. The corrected Figure 4 appears below. The order of the legend of Figure 4B,C is reversed, and the legend of Figure 4B should correspond to Figure 4C, and the legend of Figure 4C should correspond to Figure 4B. The correct legend appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 4.
Antibacterial mechanism of BBR-TA NPs. (A) Interaction of BBR, TA, BBR/TA MIX, and BBR-TA NPs with S. aureus and MRSA via SEM (scale bar = 200 nm). (B) The effect of BBR, TA, BBR/TA MIX, and BBR-TA NPs on the concentration of ATP in S. aureus cells and MRSA cells. (C) The effect of BBR, TA, BBR/TA MIX, and BBR-TA NPs on the membrane integrity of S. aureus and MRSA cells via LIVE /DEAD fixable dead cell stain assay (scale bar = 10 μm). (D) The effect of BBR, TA, BBR/TA MIX, and BBR-TA NPs on the cell cycle distribution of S. aureus and MRSA. *** p < 0.001; **** p < 0.0001.
Reference
- Zheng, T.; Chen, H.; Wu, C.; Wang, J.; Cui, M.; Ye, H.; Feng, Y.; Li, Y.; Dong, Z. Fabrication of Co-Assembly from Berberine and Tannic Acid for Multidrug-Resistant Bacteria Infection Treatment. Pharmaceutics 2023, 15, 1782. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).